New drug duo takes on Hard-to-Treat breast cancer
NCT ID NCT05266105
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called OP-1250 combined with an approved targeted therapy, palbociclib, in 60 adults with advanced or metastatic HR-positive, HER2-negative breast cancer. The goal is to find the safest dose and see if the combination can slow tumor growth. Participants must have cancer that has spread and not responded to prior treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Palazestrant (OP-1250) and palbociclib (Ibrance)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced hormone-positive breast cancer that has stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 60 participants, focused on safety and dosing. It is too small and early to know if the combination will work better than existing treatments, and side effects are still being identified.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Waratah, New South Wales, 2298, Australia
-
Clinical Trial Site
Westmead, New South Wales, 2145, Australia
-
Clinical Trial Site
South Brisbane, Queensland, 4101, Australia
-
Clinical Trial Site
Southport, Queensland, 4215, Australia
-
Clinical Trial Site
Clayton, Victoria, 3168, Australia
-
Clinical Trial Site
Frankston, Victoria, 3199, Australia
-
Clinical Trial Site
Geelong, Victoria, 3220, Australia
-
Clinical Trial Site
Nedlands, Western Australia, 6009, Australia